AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Harrow shares rise 10.38% intraday as CVS elevates Vevye to Tier 1 formulary, boosting patient access and growth prospects.
ByAinvest
Wednesday, Dec 3, 2025 12:09 pm ET1min read
Harrow (HROW) surged 10.38% intraday after CVS Health elevated its dry eye drug Vevye to Tier 1 coverage on its pharmacy benefit manager formulary, a move expected to enhance patient access and prescription volumes. This formulary upgrade, coupled with recent investor presentations at key healthcare conferences, reinforced Harrow’s growth narrative in branded ophthalmic pharmaceuticals. Other news, including local Harrow events and unrelated UK diplomatic reviews, held no material relevance to the stock’s performance.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet